Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application?

Abstract

HomeCirculationVol. 106, No. 23Brain Natriuretic Peptide Measurement in Acute Coronary Syndromes Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBBrain Natriuretic Peptide Measurement in Acute Coronary SyndromesReady for Clinical Application? James A. de Lemos, MD and David A. Morrow, MD, MPH James A. de LemosJames A. de Lemos From the Donald W. Reynolds Cardiovascular Clinical Research Center, UT Southwestern Medical School, Dallas, Tex (J.d.L.); and the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (D.A.M.). Search for more papers by this author and David A. MorrowDavid A. Morrow From the Donald W. Reynolds Cardiovascular Clinical Research Center, UT Southwestern Medical School, Dallas, Tex (J.d.L.); and the Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (D.A.M.). Search for more papers by this author Originally published3 Dec 2002https://doi.org/10.1161/01.CIR.0000042763.07757.C0Circulation. 2002;106:2868–2870Brain (B-type) natriuretic peptide (BNP) is a 32 amino acid peptide that is synthesized and released predominantly from ventricular myocardium in response to myocyte stretch. Like atrial natriuretic peptide (ANP), BNP seems to have almost exclusively beneficial physiological properties, including balanced vasodilation, natriuresis, and inhibition of both the sympathetic nervous system and the renin-angiotensin-aldosterone axis. Attempts to exploit these properties for therapeutic benefit has led to the development of recombinant human BNP (nesiritide) for the acute treatment of decompensated heart failure, and also of novel compounds that inhibit neutral endopeptidase, an enzyme that is partially responsible for BNP degradation.See p 2913Measurement of BNP in Patients With Suspected Heart FailureIn patients with heart failure, the cardiac neurohormonal system is activated, and circulating plasma levels of ANP, BNP, and the N-terminal fragments of their prohormones (N-proANP and N-proBNP) are elevated. Compared with ANP and N-proANP, BNP and N-proBNP undergo a greater proportional rise in disease states (ie, higher “signal-to-noise” ratio), and thus have emerged as the preferred biomarkers for clinical development. With commercially available assays now available, measurement of BNP or N-proBNP can be integrated readily into the care of patients with suspected heart failure. Although data are limited, BNP and N-proBNP seem to provide qualitatively similar information, and for purposes of this editorial, will be referred to interchangeably.Incorporation of BNP measurement into the clinical evaluation facilitates the diagnosis of heart failure due to either left ventricular (LV) systolic or diastolic dysfunction; a normal BNP level virtually rules out the diagnosis of decompensated heart failure, whereas a markedly elevated BNP has a high positive predictive value for heart failure.1 Although BNP levels are correlated with age, sex, intracardiac filling pressures, LV mass and ejection fraction (LVEF), renal function, and symptoms, BNP provides prognostic information in patients with heart failure that is independent of these variables.2 Recently, it has been appreciated that BNP levels may be useful as a target for specific heart failure therapies3 and as a convenient and safe alternative to invasive monitoring,4 although much work remains to be done in these important areas.BNP in Acute Coronary SyndromesAfter the description of BNP elevation in patients with chronic heart failure, several investigations focused on the clinical implications of neurohormonal activation after acute myocardial infarction (MI). BNP concentration rises rapidly over the first 24 hours after MI and then tends to stabilize; patients with a large infarct may have a second peak approximately 5 days later, perhaps reflecting the remodeling process.5 When measured 1 to 7 days after MI, BNP elevation identifies patients at risk for LV dysfunction, heart failure, and death.6,7 Here, as in chronic heart failure, the prognostic value of BNP seems to be greater than (but complimentary to) that of LVEF.6,7These initial studies of BNP in acute coronary syndromes (ACS) were small case-control studies, limited mostly to patients with ST-elevation MI, who are likely to have at least minor LV dysfunction. More recently, the prognostic application of BNP has been extended to include patients with unstable angina and non–ST-elevation MI (non–ST-elevation ACS). In a small case-control study of patients with non–ST-elevation ACS, Omland et al8 found that N-proBNP levels were higher among patients who died than those who survived. This pilot study was followed by a 2525 patient substudy of the Orbofiban in Patients with Unstable coronary Syndromes (OPUS)-TIMI 16 trial in which BNP was measured approximately 40 hours after symptom onset.9 Rates of death and heart failure through 10 months increased with higher baseline levels of BNP. This association was observed across the spectrum of ACS, including patients with ST-elevation MI, non–ST-elevation MI, and unstable angina, those with and without elevated troponin I, and those with and without clinical evidence of heart failure. In multivariate analyses, the association between BNP and mortality was independent of age, renal function, evidence of heart failure, ST deviation, troponin I, and C-reactive protein (CRP).9 More recently, in a consecutive series of patients with chest pain and no ST elevation on the presenting ECG, Jernberg et al10 found that N-proBNP levels measured at admission were strongly associated with long-term mortality, again independent of ECG changes, troponin levels, and the index diagnosis (MI versus unstable angina).In this issue of Circulation, Omland et al11 report findings from a cohort study in which N-proBNP levels were measured approximately 3 days after ACS and correlated with outcomes over an average follow-up period of more than 4 years. This study is important for several reasons. First, most previous studies demonstrating the prognostic value of BNP (or N-proBNP) in patients with non–ST-elevation ACS were substudies within randomized controlled trials and thus may have enrolled highly selected patients. More importantly, prior studies of BNP in non–ST-elevation ACS did not include routine measurement of LVEF, and concern has been raised that the association between BNP and mortality was confounded by LV dysfunction. In the present study, Omland et al11 enrolled a heterogeneous, unselected patient population and performed routine echocardiography, thus directly addressing the primary limitations of prior analyses. After adjusting for potential confounders, including age, Killip Class, and LVEF, an N-proBNP level above the median remained associated with long-term mortality. These findings were essentially unchanged after further adjustment for troponin T. Furthermore, the results appeared similar in patients with ST-elevation MI, non–ST-elevation MI, and unstable angina, although the small sample size limits demonstration of statistical significance in each subgroup.11One variable not reported in the study by Omland et al11 was LV mass. Because BNP levels are positively associated with LV mass, and LV hypertrophy (LVH) is associated with cardiovascular mortality, it is possible that unmeasured confounding from LVH may influence the present observations. The magnitude of risk associated with elevated BNP in this and other studies, however, is greater than would be expected if the effect were merely due to LVH.What Is the Source of BNP Elevation in ACS?BNP differs from other biomarkers used for risk-stratification in ACS, such as troponins and creatine kinase-MB, in that it is a counter-regulatory hormone that may play an active role in the response to ischemic injury. The level of BNP may reflect the size or severity of the ischemic insult, even when myocardial necrosis has not occurred. Several observations support this hypothesis. First, in experimental acute MI, BNP synthesis is augmented not only in infarcted tissue, but also in non-infarcted tissue.12 Second, BNP levels have been shown to increase transiently after uncomplicated percutaneous transluminal coronary angioplasty (PTCA), even when intracardiac filling pressures remain unchanged.13 Finally, BNP rises rapidly and transiently after exercise in patients with coronary disease, and the magnitude of BNP increase is proportional to the size of the ischemic territory.14 In aggregate, these findings suggest that transient ischemia increases wall stress and induces BNP synthesis and release in proportion to the degree of ischemic insult. Moreover, the rapid early rise in BNP levels after PTCA and exercise-induced ischemia suggests that release of stored BNP, as opposed to de novo synthesis, may be more important in the response to hemodynamic stress and ischemia than previously appreciated.Should We Measure BNP Routinely in Our Patients With Suspected ACS?The results of the important study from Omland et al11 in this issue of Circulation add to a rapidly growing body of literature demonstrating that BNP elevation is associated with an adverse prognosis, regardless of the cause of hemodynamic perturbation. For example, BNP elevation has been associated with adverse prognosis in cardiovascular conditions ranging from unstable angina to heart failure (due to either systolic or diastolic dysfunction); processes involving the right ventricle as diverse as primary pulmonary hypertension, cor pulmonale, arrhythmogenic RV dysplasia, and congenital heart disease; and even the general population.15Before a biomarker is measured routinely in clinical practice, several criteria should be met. First, rapid high-quality assays should be available at a reasonable cost. Second, the test should augment the diagnostic or prognostic value of currently available tools; and finally, the results should help to guide specific patient management decisions. Cardiac troponins T and I are examples of biomarkers that fulfill these criteria in patients with suspected ACS; they can be measured rapidly and accurately, can facilitate the diagnosis of acute MI, and can help to guide decisions with respect to the choice and intensity of antiplatelet, antithrombotic, and interventional strategies. Similarly, the 12-lead ECG helps to make the diagnosis of ischemia, provides important prognostic information, and directly guides therapeutic decisions. In patients with suspected heart failure, BNP (and N-proBNP) seem to fulfill most of these criteria, although more work remains to determine the optimal decision-limits for clinical interpretation, as well as the specific therapeutic implications of persistent BNP elevation.In patients with suspected ACS, BNP and N-proBNP clearly add important and unique prognostic information, but to date we do not know how this information should be used to inform clinical decision-making. Because BNP levels are associated with LV dysfunction as well as the extent of coronary disease, one might presume that patients presenting with non–ST-elevation ACS and an elevated BNP level may derive incremental benefit from an early invasive management strategy, as has been demonstrated for troponin T and I. A preliminary report from the Treat angina with Aggrastat and determine Costs of Therapy with Invasive or Conservative Strategies (TACTICS)-TIMI 18 study, however, does not support this hypothesis. There was no difference in the benefit of the early invasive strategy between patients with and without BNP elevation.16Clinical investigation of BNP in general, and in particular its application in ACS, is still in its infancy. Whereas the prognostic association between BNP and subsequent heart failure and death is now clear, directed efforts are needed to address the therapeutic implications of BNP elevation. In addition, many other specific issues need to be resolved. For example, the optimal timing of measurement is not yet clear, although in studies performed to date the association between BNP and mortality seems to be relatively independent of the timing of measurement. In addition, for clinical use, it will be helpful to define specific threshold value(s), but this may be complicated by the effects of age, sex, and assay characteristics on neurohormone levels. Finally, direct comparisons of BNP and N-proBNP are needed.ConclusionsThe report by Omland et al11 answers several critical questions and contributes to a consistent emerging message: in patients with ACS, BNP adds important prognostic information to clinical and laboratory variables, including ECG and echo findings, as well as levels of troponins and CRP. The magnitude of the risk relationship associated with BNP seems to be greater than that associated with most currently available markers. Clearly, BNP is telling us something that we did not previously know about factors associated with risk in patients with ACS. The consistent findings from Omland and others support the emerging concept that, along with a careful history and physical examination, the evaluation of a panel of several pathobiologically distinct biomarkers will provide an optimal assessment of risk in ACS.17The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.The TIMI Study Group has received research support from Biosite, Inc, the manufacturer of a B-type natriuretic peptide assay.FootnotesCorrespondence to James de Lemos, MD, UT Southwestern Medical Center, 5323 Harry Hines Blvd, CS 7.102, Dallas, TX 75390-9047. E-mail [email protected] References 1 Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161–167.CrossrefMedlineGoogle Scholar2 Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 1587–1593.CrossrefMedlineGoogle Scholar3 Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126–1130.CrossrefMedlineGoogle Scholar4 Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001; 7: 21–29.CrossrefMedlineGoogle Scholar5 Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993; 88: 82–91.CrossrefMedlineGoogle Scholar6 Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93: 1963–1969.CrossrefMedlineGoogle Scholar7 Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998; 97: 1921–1929.CrossrefMedlineGoogle Scholar8 Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002; 89: 463–465.CrossrefMedlineGoogle Scholar9 de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014–1021.CrossrefMedlineGoogle Scholar10 Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40: 437–445.CrossrefMedlineGoogle Scholar11 Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002; 106: 2913–2918.LinkGoogle Scholar12 Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995; 92: 1558–1564.CrossrefMedlineGoogle Scholar13 Tateishi J, Masutani M, Ohyanagi M, et al. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000; 23: 776–780.CrossrefMedlineGoogle Scholar14 Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Colch). 1995; 88: 551–556.CrossrefGoogle Scholar15 McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 2001; 86: 21–26.CrossrefMedlineGoogle Scholar16 Morrow DA, de Lemos JA, Sabatine MS, et al. Detection of cardiac neurohormonal activation complements cardiac troponin for predicting recurrent events in UA/NSTEMI: prognostic utility of BNP in TACTICS-TIMI 18. J Am Coll Cardiol. 2002; 2002: 304A. Abstract.Google Scholar17 Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002; 105: 1760–1763.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Falcão F, Oliveira F, Cantarelli F, Cantarelli R, Brito Júnior P, Lemos H, Silva P, Camboim I, Freire M, Carvalho O and Sobral Filho D (2020) Carbohydrate antigen 125 for mortality risk prediction following acute myocardial infarction, Scientific Reports, 10.1038/s41598-020-67548-8, 10:1, Online publication date: 1-Dec-2020. 张 超 (2020) Analysis of Susceptibility Factors and Related Predictors of the Coronary Artery Triple-Vessel Lesion, Advances in Clinical Medicine, 10.12677/ACM.2020.107218, 10:07, (1450-1456), . Leira Y and Blanco J (2018) Brain natriuretic peptide serum levels in periodontitis, Journal of Periodontal Research, 10.1111/jre.12547, 53:4, (575-581), Online publication date: 1-Aug-2018. Riddell E and Vader J (2017) Potential Expanded Indications for Neprilysin Inhibitors, Current Heart Failure Reports, 10.1007/s11897-017-0327-y, 14:2, (134-145), Online publication date: 1-Apr-2017. Mohan G, Kaur R and Singh T (2017) Cardiac Biomarkers in Acute Coronary Syndrome, AMEI's Current Trends in Diagnosis & Treatment, 10.5005/jp-journals-10055-0019, 1:2, (80-88), Online publication date: 1-Dec-2017. Sultan P, Seligman K and Carvalho B (2016) Amniotic fluid embolism, Current Opinion in Anaesthesiology, 10.1097/ACO.0000000000000328, 29:3, (288-296), Online publication date: 1-Jun-2016. Cheng J, Akkerhuis K, Meilhac O, Oemrawsingh R, Garcia-Garcia H, van Geuns R, Piquer D, Merle D, du Paty E, Galéa P, Jaisser F, Rossignol P, Serruys P, Boersma E, Fareh J and Kardys I (2014) Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography, Arteriosclerosis, Thrombosis, and Vascular Biology, 34:5, (1078-1084), Online publication date: 1-May-2014. Wei P, Wang H, Fu Q, Bai J and Zhu Q (2013) Levels of BNP and Stress Blood Glucose in Acute Coronary Syndrome Patients and Their Relationships with the Severity of Coronary Artery Lesion, Cell Biochemistry and Biophysics, 10.1007/s12013-013-9734-1, 68:3, (535-539), Online publication date: 1-Apr-2014. Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey D, Chavey W, Fesmire F, Hochman J, Levin T, Lincoff A, Peterson E, Theroux P, Wenger N, Wright R, Zoghbi W, Arend T, Oetgen W, May C, Bradfield L, Keller S, Ramadhan E, Tomaselli G, Brown N, Robertson R, Whitman G, Bezanson J and Hundley J (2013) 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction, Circulation, 127:23, (e663-e828), Online publication date: 11-Jun-2013. Zeng K, Wu X, Liu Q, Gao F and Lin C (2012) Impact of a novel mutation in the 5′-flanking region of natriuretic peptide precursor B gene on the antihypertensive effects of sodium nitroprusside in patients with hypertension, Journal of Human Hypertension, 10.1038/jhh.2012.25, 27:4, (271-276), Online publication date: 1-Apr-2013. Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey D, Chavey W, Fesmire F, Hochman J, Levin T, Lincoff A, Peterson E, Theroux P, Wenger N and Wright R (2013) 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction, Journal of the American College of Cardiology, 10.1016/j.jacc.2013.01.014, 61:23, (e179-e347), Online publication date: 1-Jun-2013. Tousoulis D, Androulakis E and Papageorgiou N (2013) Novel Biomarkers Used in the Assessment of Acute Coronary Syndrome Biomarkers in Cardiovascular Diseases, 10.1201/b15301-16, (345-362), Online publication date: 5-Aug-2013. White H (2012) Biomarkers in acute coronary syndromes Advances in Acute Coronary Syndrome Management, 10.2217/ebo.11.333, (18-29), Online publication date: 1-Mar-2012. Ashavaid T, Ponde C, Shah S and Jawanjal M (2012) Cardiovascular Disease in India, Clinics in Laboratory Medicine, 10.1016/j.cll.2012.04.001, 32:2, (217-230), Online publication date: 1-Jun-2012. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I and Karouia A (2012) The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery, Perfusion, 10.1177/0267659112454155, 27:6, (504-511), Online publication date: 1-Nov-2012. Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey D, Chavey W, Fesmire F, Hochman J, Levin T, Lincoff A, Peterson E, Theroux P, Wenger N and Wright R (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction, Circulation, 123:18, (e426-e579), Online publication date: 10-May-2011. Wetmore J, Gadi R, Lee J, O'Keefe J, Chan P, Tang F and Spertus J (2011) Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis, BMC Research Notes, 10.1186/1756-0500-4-542, 4:1, Online publication date: 1-Dec-2011. Wilson P (2011) Prediction of Cardiovascular Disease Events, Cardiology Clinics, 10.1016/j.ccl.2010.10.004, 29:1, (1-13), Online publication date: 1-Feb-2011. Wright R, Anderson J, Adams C, Bridges C, Casey D, Ettinger S, Fesmire F, Ganiats T, Jneid H, Lincoff A, Peterson E, Philippides G, Theroux P, Wenger N and Zidar J (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction, Journal of the American College of Cardiology, 10.1016/j.jacc.2011.02.011, 57:19, (e215-e367), Online publication date: 1-May-2011. Waks J and Scirica B (2011) Established and novel biomarkers in ST-elevation myocardial infarction, Future Cardiology, 10.2217/fca.11.31, 7:4, (523-546), Online publication date: 1-Jul-2011. Singh V, Martinezclark P, Pascual M, Shaw E and O'Neill W (2010) Cardiac biomarkers – the old and the new: a review, Coronary Artery Disease, 10.1097/MCA.0b013e328338cd1f, 21:4, (244-256), Online publication date: 1-Jun-2010. Christenson R (2009) Cardiac Markers: A Chest Pain Center Focus Short Stay Management of Chest Pain, 10.1007/978-1-60327-948-2_7, (91-113), . Pérez Surribas D, Cárdenas Fernández M, Cortés Rius M, Fernández García M, García Montes M, Llompart Alabern I, Rodríguez González T, Valldecabres Ortiz C, Viedma Contreras J, Zapico Muñiz E and Martínez Bru C (2009) Nuevos marcadores en el síndrome coronario agudo, Revista del Laboratorio Clínico, 10.1016/j.labcli.2008.10.002, 2:1, (34-46), Online publication date: 1-Jan-2009. Ang D, Kong C, Kao M and Struthers A (2009) Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities, American Heart Journal, 10.1016/j.ahj.2009.04.024, 158:1, (133-140), Online publication date: 1-Jul-2009. Villacorta J, Oddoze C, Giorgi R, Kerbaul F, Bonnet M, Collart F, Gouin F and Guidon C (2008) Postoperative Treatment With Angiotensin-Converting Enzyme Inhibitors in Patients With Preoperative Reduced Left Ventricular Systolic Function, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2007.06.004, 22:2, (187-191), Online publication date: 1-Apr-2008. Loria V, Leo M, Biasillo G, Dato I and Biasucci L (2008) Biomarkers in Acute Coronary Syndrome, Biomarker Insights, 10.4137/BMI.S588, 3, (BMI.S588), Online publication date: 1-Jan-2008. Bonaca M and Morrow D (2008) Defining a Role for Novel Biomarkers in Acute Coronary Syndromes, Clinical Chemistry, 10.1373/clinchem.2008.105387, 54:9, (1424-1431), Online publication date: 1-Sep-2008. Vergès B, Zeller M, Beer J and Cottin Y (2008) Plasma N-terminal Pro-Brain Natriuretic Peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes, Diabetes & Metabolism, 10.1016/S1262-3636(08)70097-1, 34, (10-15), Online publication date: 1-Feb-2008. Godkar D, Bachu K, Dave B, Niranjan S and Khanna A (2008) B-Type Natriuretic Peptide (BNP) and ProBNP: Role of Emerging Markers to Guide Therapy and Determine Prognosis in Cardiovascular Disorders, American Journal of Therapeutics, 10.1097/MJT.0b013e31815af96f, 15:2, (150-156), Online publication date: 1-Mar-2008. Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey D, Chavey W, Fesmire F, Hochman J, Levin T, Lincoff A, Peterson E, Theroux P, Wenger N, Wright R, Smith S, Jacobs A, Adams C, Anderson J, Antman E, Halperin J, Hunt S, Krumholz H, Kushner F, Lytle B, Nishimura R, Ornato J, Page R and Riegel B (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction, Journal of the American College of Cardiology, 10.1016/j.jacc.2007.02.013, 50:7, (e1-e157), Online publication date: 1-Aug-2007. MARÍN-GARCÍA J (2007) Future of Post-Genomic Cardiology Post-Genomic Cardiology, 10.1016/B978-012373698-7/50020-6, (619-636), . Maisel A, Bhalla V and Braunwald E (2006) Cardiac biomarkers: a contemporary status report, Nature Clinical Practice Cardiovascular Medicine, 10.1038/ncpcardio0405, 3:1, (24-34), Online publication date: 1-Jan-2006. Clerico A, Recchia F, Passino C and Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00684.2005, 290:1, (H17-H29), Online publication date: 1-Jan-2006. Carreiro-Lewandowski E (2006) Update on Cardiac Biomarkers, Laboratory Medicine, 10.1309/LYJ8PL6A7A4FJWCA, 37:10, (597-605), Online publication date: 1-Oct-2006. Navarro Estrada J, Rubinstein F, Bahit M, Rolandi F, de Arenaza D, Gabay J, Alvarez J, Sarmiento R, Matas C, Sztejfman C, Tettamanzi A, de Miguel R and Guzman L (2006) NT–probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non–ST-elevation acute coronary syndromes, American Heart Journal, 10.1016/j.ahj.2005.12.020, 151:5, (1093.e1-1093.e7), Online publication date: 1-May-2006. Iltumur K, Karabulut A, Apak I, Aluclu U, Ariturk Z and Toprak N (2006) Elevated plasma N-terminal pro–brain natriuretic peptide levels in acute ischemic stroke, American Heart Journal, 10.1016/j.ahj.2005.05.022, 151:5, (1115-1122), Online publication date: 1-May-2006. Ogawa A, Seino Y, Yamashita T, Ogata K and Takano T (2006) Difference in Elevation of N-Terminal Pro-BNP and Conventional Cardiac Markers Between Patients With ST Elevation vs Non-ST Elevation Acute Coronary Syndrome, Circulation Journal, 10.1253/circj.70.1372, 70:11, (1372-1378), . Morrow D (2006) A Multimarker Approach to Evaluation of Patients With Acute Coronary Syndrome Cardiovascular Biomarkers, 10.1007/978-1-59745-051-5_31, (545-558), . Puyó A, Scaglione J, Auger S, Cavallero S, Postan M and Fernández B (2005) Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease, Regulatory Peptides, 10.1016/j.regpep.2005.01.001, 128:3, (203-210), Online publication date: 1-Jun-2005. Struthers A and Davies J (2005) B-type natriuretic peptide: a simple new test to identify coronary artery disease?, QJM: An International Journal of Medicine, 10.1093/qjmed/hci111, 98:10, (765-769), Online publication date: 1-Oct-2005. Vergès B, Zeller M, Desgrès J, Dentan G, Laurent Y, Janin-Manificat L, L'Huillier I, Rioufol G, Beer J, Makki H, Rochette L, Gambert P and Cottin Y (2005) High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock, European Heart Journal, 10.1093/eurheartj/ehi260, 26:17, (1734-1741), Online publication date: 1-Sep-2005. Yeo K, Dumont K and Brough T (2005) Elecsys NT-ProBNP and BNP Assays: Are There Analytically and Clinically Relevant Differences?, Journal of Cardiac Failure, 10.1016/j.cardfail.2005.04.017, 11:5, (S84-S88), Online publication date: 1-Jun-2005. Cerisano G, Pucci P, Valenti R, Boddi V, Migliorini A, Tommasi M, Raspanti S, Parodi G and Antoniucci D (2005) Comparison of the usefulness of Doppler-derived deceleration time versus plasma brain natriuretic peptide to predict left ventricular remodeling after mechanical revascularization in patients with ST-elevation acute myocardial infarction and left ventricular systolic dysfunction, The American Journal of Cardiology, 10.1016/j.amjcard.2004.12.029, 95:8, (930-934), Online publication date: 1-Apr-2005. Tarnow L, Hildebrandt P, Hansen B, Borch-Johnsen K and Parving H (2004) Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy, Diabetologia, 10.1007/s00125-004-1595-0, 48:1, (149-155), Online publication date: 1-Jan-2005. Virmani R, Farb A and Kolodgie F (2005) Drug eluting stents Local Drug Delivery for Coronary Artery Disease, 10.3109/9780203640388-65, (572-580), Online publication date: 14-Jun-2005. Markham D and de Lemos J (2005) Screening for cardiovascular disease using B-type natriuretic peptides: detecting an imbalance of the four humoursThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology., European Heart Journal, 10.1093/eurheartj/ehi470, 26:21, (2220-2221), Online publication date: 1-Nov-2005. Palazzuoli A, Carrera A, Calabria P, Pastore M, Quatrini I, Vecchiato L, Campagna M, Palazzuoli V and Nuti R (2004) Brain natriuretic peptide levels during cardiac reperfusion: comparison between percutaneous coronary angioplasty and aorto-coronaric bypass, Clinica Chimica Acta, 10.1016/j.cccn.2003.11.021, 342:1-2, (87-92), Online publication date: 1-Apr-2004. Wiviott S, de Lemos J and Morrow D (2004) Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes, Clinica Chimica Acta, 10.1016/j.cccn.2004.04.004, 346:2, (119-128), Online publication date: 1-Aug-2004. Sadanandan S, Cannon C, Chekuri K, Murphy S, DiBattiste P, Morrow D, de Lemos J, Braunwald E and Gibson C (2004) Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction, Journal of the American College of Cardiology, 10.1016/j.jacc.2004.03.072, 44:3, (564-568), Online publication date: 1-Aug-2004. Galvani M, Ferrini D and Ottani F (2004) Natriuretic peptides for risk stratification of patients with acute coronary syndromes, European Journal of Heart Failure, 10.1016/j.ejheart.2004.01.006, 6:3, (327-333), Online publication date: 1-Mar-2004. Chan M and Pronovost P (2004) Clinical utility of biomarkers in myocardial injury, Current Opinion in Anaesthesiology, 10.1097/00001503-200402000-00008, 17:1, (49-55), Online publication date: 1-Feb-2004. de Winter R, Stroobants A, Koch K, Bax M, Schotborgh C, Mulder K, Sanders G, van Straalen J, Fischer J, Tijssen J and Piek J (2004) Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention, The American Journal of Cardiology, 10.1016/j.amjcard.2004.08.023, 94:12, (1481-1485), Online publication date: 1-Dec-2004. Cosson S (2004) Usefulness of B-type Natriuretic Peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus, Diabetes & Metabolism, 10.1016/S1262-3636(07)70132-5, 30:4, (381-386), Online publication date: 1-Sep-2004. Kerbaul F, Giorgi R, Oddoze C, Collart F, Guidon C, Lejeune P, Villacorta J and Gouin F (2004) High concentrations of N-BNP are related to non-infectious severe SIRS associated with cardiovascular dysfunction occurring after off-pump coronary artery surgery †, British Journal of Anaesthesia, 10.1093/bja/aeh246, 93:5, (639-644), Online publication date: 1-Nov-2004. Kerbaul F, Collart F, Giorgi R, Oddoze C, Lejeune P, Guidon C, Caus T, Bellezza M and Gouin F (2004) Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery, Intensive Care Medicine, 10.1007/s00134-004-2299-0, 30:9, (1799-1806), Online publication date: 1-Sep-2004. Panteghini M (2004) Biochemical markers of cardiac diseases, Jugoslovenska medicinska biohemijaYugoslav Medical Biochemistry, 10.2298/JMH0403201P, 23:3, (201-211), . Ollivier J and Revel F (2004) Peptide natriurétique B et syndromes coronariens aigus : Utilité du dosage du fragment NT-pro BNP, Bulletin de l'Académie Nationale de Médecine, 10.1016/S0001-4079(19)33627-1, 188:9, (1529-1540), Online publication date: 1-Dec-2004. Morrow D and Braunwald E (2003) Future of Biomarkers in Acute Coronary Syndromes, Circulation, 108:3, (250-252), Online publication date: 22-Jul-2003. Domínguez Rodríguez A, Amaro León M and Burillo-Putze G (2003) Cartas al Editor, Medicina Clínica, 10.1016/S0025-7753(03)73930-X, 121:8, (317), Online publication date: 1-Jan-2003. Ruskoaho H (2016) Cardiac Hormones as Diagnostic Tools in Heart Failure, Endocrine Reviews, 10.1210/er.2003-0006, 24:3, (341-356), Online publication date: 1-Jun-2003. Morrow D, de Lemos J, Sabatine M, Murphy S, Demopoulos L, DiBattiste P, McCabe C, Gibson C, Cannon C and Braunwald E (2003) Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non–ST-elevation myocardial infarction, Journal of the American College of Cardiology, 10.1016/S0735-1097(03)00168-2, 41:8, (1264-1272), Online publication date: 1-Apr-2003. Bostan M, Stătescu C, Anghel L, Șerban I, Cojocaru E and Sascău R (2020) Post-Myocardial Infarction Ventricular Remodeling Biomarkers—The Key Link between Pathophysiology and Clinic, Biomolecules, 10.3390/biom10111587, 10:11, (1587) Busardò F, Frati P, Zaami S and Fineschi V (2015) Amniotic Fluid Embolism Pathophysiology Suggests the New Diagnostic Armamentarium: β-Tryptase and Complement Fractions C3-C4 Are the Indispensable Working Tools, International Journal of Molecular Sciences, 10.3390/ijms16036557, 16:12, (6557-6570) Falcão F, Oliveira F, Cantarelli F, Cantarelli R, Brito-Júnior P, Lemos H, Silva P, Camboim I, Freire M, Carvalho O and Sobral-Filho D (2019) Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction, Brazilian Journal of Medical and Biological Research, 10.1590/1414-431x20199124, 52:12 Xie H, Yan Z, Feng S, Zhu T, Zhu Z, Ni J, Ni J, Du R, Zhu J, Ding F, Liu S, Han H, Zhang H, Zhao J, Zhang R, Quan W and Yan X (2020) Prognostic Value of Circulating MG53 Levels in Acute Myocardial Infarction, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2020.596107, 7 December 3, 2002Vol 106, Issue 23 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000042763.07757.C0PMID: 12460861 Originally publishedDecember 3, 2002 Keywordscoronary diseasenatriuretic peptidesEditorialsPDF download Advertisement